John Poyhonen

John Poyhonen (chief executive) discloses dealings in 3 companies, chiefly Senomyx Inc, Heron Therapeutics, Inc. /DE/ and Intrabiotics Pharmaceuticals Inc /DE. The record holds 76 filings, for trades running from 17 January 2006 to 13 April 2023.

In open-market terms, that means 5 purchases worth €289k on one side and 24 sales worth €1.0M on the other. The net balance comes to €727k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 20 share grants and 22 option exercises.

A typical purchase (the median) is worth €47k.

The newest entry dates from 17 April 2023: an option exercise, in Heron Therapeutics, Inc. /DE/. The latest purchase dates back some time: it was published 2,577 days ago, on 4 October 2019. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.